David:
ARQL has been painful. It's the primary reason that, while my trading has been mega-successful, I'm sort of treading water of late. :-(
Nope, the recent volume was "overhang". It has been open-market, institution-to-institution trades. The price is negotiated down for low-volume issues, and, when a market maker can make a hole by taking out the existing bids, pow! I believe that the "bail" this time may have been executed by Sevin Rosen.
And, nope..... much of their business plan is built around homeruns. The AHP (Wyeth Ayerst) program, you're correct, is not homerun material. It's damn healthy "multiple doubles" material, however. The homerun programs are biotech-biotech collaborations, where companies with biological screens but little chem capacity are floating ARQL chemical libraries in front of the screens.
ARQL is my third largest holding. I urge caution, as the number of shares that have been dumped by VCs and insiders has been frightening, and I don't know when it will end. OTOH, when it does, life will be wonderful. Here's a link giving my impression.........
Message 3926378
Rick
|
